Table 4.

Multivariable model for the composite outcome of incident kidney disease and deatha

ParameterCreatinine Based (HR [95% CI])eGFR Based (HR [95% CI])
Serum uric acid (per 1-mg/dl increase)1.09 (1.06 to 1.13)1.08 (1.05 to 1.12)
Age (per 10-yr increase)2.33 (2.16 to 2.52)2.34 (2.17 to 2.53)
Female gender0.71 (0.63 to 0.80)0.77 (0.69 to 0.85)
Black race1.43 (1.27 to 1.62)1.32 (1.17 to 1.48)
History of CVD2.01 (1.83 to 2.21)1.88 (1.72 to 2.06)
History of diabetes2.16 (1.94 to 2.41)2.03 (1.82 to 2.62)
History of hypertension1.15 (1.03 to 1.28)1.16 (1.05 to 1.29)
Current smoking2.28 (2.06 to 2.52)2.06 (1.87 to 2.27)
Current alcohol0.88 (0.80 to 0.96)0.89 (0.81 to 0.97)
High school graduate0.71 (0.65 to 0.78)0.76 (0.69 to 0.83)
SBP (per 10-mmHg increase)1.11 (1.08 to 1.13)1.11 (1.09 to 1.13)
Total cholesterol (per 10-mg/dl increase)1.01 (1.00 to 1.02)1.01 (1.00 to 1.02)
HDL cholesterol (per 5-mg/dl increase)1.00 (0.98 to 1.01)1.00 (0.99 to 1.02)
Baseline kidney function1.04 (1.01 to 1.06)0.95 (0.93 to 0.98)
Serum albumin (per 1-g/dl increase)0.52 (0.44 to 0.60)0.57 (0.49 to 0.67)
Hematocrit (per 2% increase)0.99 (0.97 to 1.02)0.98 (0.96 to 1.01)
ARIC (versus CHS)0.97 (0.82 to 1.15)0.95 (0.80 to 1.12)
  • a Creatinine-based outcomes are defined by an increase in serum creatinine of ≥0.4 mg/dl where baseline serum creatinine was ≤1.4 mg/dl in men and ≤1.2 mg/dl in women and final serum creatinine was above these levels. eGFR-based outcomes are defined by a decrease in eGFR of ≥15 ml/min per 1.73 m2 where the initial eGFR was ≥60 ml/min per 1.73 m2 and the final eGFR was <60 ml/min per 1.73 m2. Baseline kidney function is assessed by serum creatinine in creatinine-based models with the OR reflecting each 0.1-mg/dl rise and by eGFR in eGFR-based models with OR reflecting each 10-ml/min per 1.73 m2 rise.